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Mechanosensitive transient receptor potential
vanilloid type 1 channels contribute to vascular
remodeling of rat fistula veins
Yih-Sharng Chen, MD, PhD,a Ming-Jen Lu, MD,b Ho-Shiang Huang, MD, PhD,c and
Ming-Chieh Ma, PhD,d Taipei and Hsinchuang, Taiwan
Objective: We previously showed that matrix metalloproteinases (MMPs) contribute to tremendous blood flow-induced
venous wall thickening during the maturation of an arteriovenous fistula (AVF). However, how veins in the fistula sense a
dramatic change in the blood flow remains unknown. Becausemechanosensitive transient receptor potential vanilloid channels
(TRPVs)arepresent in theendothelium,weexaminedwhether theCa2-permeableTRPVsplaya role in remodelingoffistulaveins.
Methods: The fistula veins were generated at femoral AVF of Wistar rats. Changes in the hemodynamics and the width and
internal radius of the iliac vein were studied at 3, 7, 14, and 28 days, then the iliac vein was removed and examined for changes
in wall thickness and protein or mRNA expression by immunofluorecent stain, Western blot, or real time PCR. Changes in
MMP2 activity was examined by gelatin zymography. Two ligatures were performed in iliac vein to prevent venodilatation to
confirm the effect of dramatic changes in hemodynamics on TRPV expression. The specific role of TRPVwas studied in another
group of fistula veins given with capsazepine via a subcutaneous mini-osmotic pump for 28 days.
Results: The fistula veins demonstrated high flow/wall shear stress (WSS), wall thickening, and venodilatation compared
with control veins. TheWSS increase was positively correlated with upregulation of TRPV1, but not TRPV4. Narrowing
fistula veins prevented TRPV1 upregulation, indicating that high flow directly upregulates TRPV1. We examined the
underlying signaling components and found that enhanced Ca2/calmodulin-dependent protein kinase II (CaMK II)
activity upregulated endothelial nitric oxide synthase (eNOS) and downregulated arginase I in the fistula veins. These
changes were reversed by a CaMK II inhibitor. The relative levels of eNOS and arginase I activity consequently
augmented NO formation, which coincided with an increase in MMP2 activity. Chronic inhibition of TRPV1 in the
fistula veins by capsazepine showed no effect on high flow and TRPV1 expression, but markedly attenuated WSS, which
was concomitantly associated with attenuation of CaMK II activity, NO-dependent MMP2 activation, and remodeling.
Conclusion: These findings indicate that TRPV1 is essential in the remodeling of AVFs and that WSS leads to TRPV1
upregulation, which then enhances remodeling, therefore, inhibition of TRPV1 pathway may prolong the lifespan of an
AVF by decreasing WSS and vein wall remodeling. (J Vasc Surg 2010;52:1310-20.)
Clinical Relevance: This study reveals that enhanced endothelial mechanosensation is requisite for the fistula remodeling
in response to dramatic hemodynamic changes. Moreover, our findings demonstrate that Ca2 signal triggered by
TRPV1 upregulates eNOS and downregulates arginase I and which enhances NO formation to lead to MMP2 activation
in extracellular matrix remodeling of fistula veins. These findings enhance understanding of the basic biologic mecha-
nisms in the venous remodeling. The need for TRPV1-mediated remodeling suggests that clinical strategies to blunt
mechanosensation of fistula veins during maturation might be more successful or prolong the life span of fistula veins if
TRPV1 are inhibited as a part of the surgical or follow-up treatment.An arteriovenous fistula (AVF) is the preferred vascular
access for patients with end-stage renal disease requiring
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1310hemodialysis.1 Following surgical creation, fistula veins are
immediately challenged with a tremendous blood flow and
high wall shear stress (WSS), and the lumen gradually dilates
to reduce WSS.1,2 Growth of new cells and formation new
matrix in the venouswall results inwall thickening of intima or
media while greatly increasing the risk of AVF failure.2,3
Therefore, strategies that can optimize remodeling of the
fistula veins but without affecting venodilation and hemody-
namic changes are needed to prolong the useful lifespan of the
AVF. We showed previously that a rat AVF created at the
femoral artery and vein shares features similar to clinically
generated AVF constructed for hemodialysis, ie, high blood
flow and low pressure are seen in the fistula veins, and changes
in the collagen deposition and tissue expression of matrix
metalloproteinases (MMPs) and tissue inhibitor of metallo-
proteinases are responsible for venous remodeling.4However,
how the increased blood flow is detected by the fistula vein to
induce vascular remodeling by MMPs is unknown.
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ing the physical force of blood flow or WSS to biochemical
signaling, which controls the plasticity of the underlying
smooth muscle cells (SMCs).5 Among various cellular sig-
nals, Ca2-dependent mechanotransduction for releasing
vasoactive substances such as nitric oxide (NO) plays an
important role in the regulation of tissue perfusion.6 Im-
pairment in sensing the flow-generated WSS attenuates
vasodilatation and is recognized as a hallmark of endothelial
dysfunction in various presentations of cardiovascular dis-
eases.7 In the dog AVF, chronic increases in blood flow
enhance the response of endothelium- and NO-dependent
vasodilatation to acetylcholine and 2-adrenergic stimula-
tion in fistula veins.8 Moreover, studies in rats showed that
chronic increases in blood flow in the aorta and in the
mesenteric artery, caused by an aortocaval fistula and aortic
ligation, respectively, enhanced expression of endothelial
NO synthase (eNOS), whereas reduction of blood flow
decreased eNOS expression.9,10 These observations indi-
cate that NO generated by enhanced eNOS function is
important for fistula vessels in their adaptation to increased
blood flow. However, how fistula vessels adapt increased
blood flow well by enhanced eNOS function and NO
generation is unclear.
Different members of the transient receptor potential
channel (TRP) family have been identified in the endothe-
lium.7 Of particular interest in mechanotransduction are
the TRP vanilloid (TRPV) subfamily because both TRPV1
and TRPV4 play a role in regulation of vascular tone.7,11,12
The presence of TRPV4 in the endothelium of the rat
carotid artery is a response to increased WSS and causes
endothelium-dependent vasodilatation.12 TRPV1 not only
functions as an endothelial vasorelaxant, but also acts as a
mechanoreceptor or mechanotransducer in the renal pelvis,
bladder, and carotid sinus in response to elevation of the
intraluminal hydrostatic pressure.13-15 Moreover, a few
studies have detected functional TRPVs in fistula veins.
These observations led us to formulate the hypothesis that
TRPV present in the venous endothelium may act as a
mechanosensor to detect the increases in flow/WSS after
AVF creation. NO plays a key role in the control of MMP
activity in flow-induced remodeling.16 We therefore as-
sessed whether NO-dependent MMP stimulation is regu-
lated by TRPVs in vascular remodeling of the fistula vein.
METHODS
AVF creation in rats. The experimental protocols
used 200 to 220 g female Wistar rats (Laboratory Animal
Center, National Taiwan University, Taipei, Taiwan) and
were approved by the Institutional Animal Care and Use
Committee. The arteriovenous anastomosis at the left fem-
oral artery and vein (Fig 1, A) was created as described
previously.4 Briefly, the fistula veins were generated by
invagination of distal end of the left femoral artery into the
femoral vein after venotomy. A ligature between the two
vessels using 8-0 silk is enough to prevent the artery from
detaching after reflow. In the control veins, the left femoral
artery was cut, but invagination was not performed. Tem-poral changes in hemodynamics and vein thickness were
examined 0, 3, 7, 14, or 28 days postoperatively.
Hemodynamic measurements. On the experiment
day, animals were anesthetized with intraperitoneal pento-
barbital sodium (50 mg kg1). After a midline laparotomy
was performed to expose the lower abdominal vessels, the
external width (mm) of the left iliac vein was determined
from photographs taken with a calibrated scale. The iliac
vein (2 cm cephalad of the fistula) was then isolated from
the surrounding tissue to measure the blood flow (Q, mL
min1) using a flowmeter (Transonic, Ithaca, NY). The
pressure in the veins was measured by direct puncture with
a 30-gauge needle connected to polyethylene tubing (PE-
10) and a pressure transducer.4 After cutting a 2-mm
segment of iliac vein and opening it, the length of venous
strip, ie, the circumference, was determined from photo-
graphs taken with a calibrated scale. The internal diameter
(mm) was calculated by dividing the circumference by .
WSS was estimated using   4Q/r3, where  and r are
the blood viscosity (0.035 poise) and the internal radius,17
respectively. Six rats were studied at each time point and
none showed complications such as intravascular coagula-
tion or stenosis. Then the venous strip was prepared for
histological examination and biochemical assays. Because
there was no difference in the control veins obtained at
different time-points, we pooled those samples.
Restriction of blood flow. In the separate groups,
two silk ties, 3 mm apart, were placed on the left iliac vein,
1-cm cephalad of the fistula to keep the width of the vein
	1.5 mm, after AVF creation or sham operation for 28
days (n  6 for each). This treatment significantly reduced
blood flow, from 9.8 
 1.3 to 2.6 
 0.7 mL min1
measured on the day of fistula construction.
Chronic delivery of specific inhibitors. The mini-
osmotic pumps (model 2004; Alzet, Cupertino, Calif) were
prepared as described previously with a modification.18
After filling the vehicle or drug solution in the pump, a
PE-50 tube was connected to flow moderator of pump.
The other end of PE tube was then placed into left external
jugular vein and the pump was implanted subcutaneously
according to the manufacturer’s instruction. All procedures
were performed under sterile conditions. Vehicle solution
(0.05% DMSO) or cell-permeable inhibitors of CaMK II
(KN-93, 2.0 g L1) or TRPV1 (capsazepine, Capz, 0.2
g L1) was carefully filled into pump for 28-day delivery
(n  6 for each test).
Histologic examination and immunofluorescent
staining. Sections (5 m) were prepared and stained with
hematoxylin and eosin to determine the thickness of the
intima and media as described previously.4 The stained
tissue slices were examined using imaging software with
a microruler (Spot; Diagnostic Instruments, Sterling
Heights, Mich) and the thickness of each layer was mea-
sured. The micrographs were obtained from images at
800  magnification. For immunofluorescent staining,
sections were incubated overnight at 4°C with rabbit anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, Calif)
against TRPV1 (1:1,000) or eNOS (1:1,000).4,19 Staining
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peptides (Santa Cruz Biotechnology) was used as a negative
control.
Reverse transcriptase–polymerase chain reaction
analysis (RT-PCR). SemiquantitativeRT-PCRwas used to
detect TRPV and GAPDH mRNA expression as described
previously.18,19 Briefly, total RNA in the veins was extracted.
After the RNA pellet was washed, dried, and resuspended,
cDNAwas synthesized by using 5gof the total RNA.TRPV
Fig 1. Hemodynamic changes and venous remodeling
femoral artery and vein was created by invagination of the
flow, wall shear stress (WSS), intravascular pressure, the in
time points.C, Representative images showmarked vaso
arrows in yellow) compared with the contralateral site on
and media (middle), and the ratio of intima to media (IM
time-point.and GAPDH cDNAs were amplified using specific primersdesigned as: TRPV1 sense 5=-GCG TTT GTC GAC TGA
CTG AA-3= and antisense 5=-CAG GAG TCC AGC TCA
CCT TC-3= (transcript product of 396 bases); TRPV4 sense
5=-GTG CCT GGG CCC AAG AAA-3= and antisense 5=-
GGG CAG CTC CCC AAA GTA GAA-3= (transcript prod-
uct of 579 bases); GAPDH sense 5=-TTA GCA CCC CTG
GCCAAGG-3= and antisense 5=-CTTACTCCTTGGAGG
CCA TG-3= (transcript product of 535 bases). TRPVmRNA
level was expressed as the ratio of the TRPV1 or TRPV4 and
arteriovenous fistula (AVF). A, The anastomosis of the
nd of the artery (b) into the vein (a).B, Changes in blood
al radius, and width in control and fistula veins at various
tion of the iliac vein at the fistula site (indicated by double
4 and 28.D, Changes in the thickness of intima (upper)
the veins. *P 	 .05 compared with control at the samein rat
cut e
tern
dilata
day 1
) inGAPDH PCR products.
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from venous tissue as described previously.4,18 Briefly,
Western blotting was performed using specific antibodies
(Santa Cruz Biotechnology) with appropriate dilution
against rat TPRV1 (1:1,000), TPRV4 (1:1,000), eNOS
(1:1,500), iNOS (1:1,000), arginase I (1:1,500), arginase
II (1:500), phosphorylated CaMK II (pCaMK II; 1:500),
total CaMK II (1:500), or actin (1:2,000). After being
washed, the membrane was incubated with horseradish
peroxidase-conjugated anti-rabbit or anti-mouse IgG anti-
body (Vector Laboratory, Burlingame, Calif) and bound
antibody was visualized using a commercial ECL kit (GE
Healthcare Biosciences, Pittsburgh, Pa) and Kodak film.
The densities of the bands were determined using an image
analyzing system (Diagnostic Instruments).
Zymography. MMP2 activity was assayed by gelatin
zymography.20 Gelatin (1 mg ml1) was polymerized in a
10% polyacrylamide gel. Electrophoresis was carried out at
4°C. The gel was washed twice with washing buffer (50
mmol/L Tris-HCl, pH 7.5, 100 mmol/L NaCl, 2.5%
Triton X-100), followed by a brief rinse in washing buffer
without Triton X-100. Assays were conducted in incuba-
tion buffer (50 mmol/L Tris-HCl, pH 7.5, 150 mmol/L
NaCl, 10 mmol/L CaCl2, 0.02% NaN3, and 1 mol/L
ZnCl2) at 37°C for 18 hours and visualized by Coomassie
Blue R-250 staining. Gelatin digestion appeared as a clear
zone.
Determination of NO metabolites. Venous samples
were prepared according to the manufacturer’s instructions
and analyzed in duplicate using a commercial kit for nitrate
and nitrite (Cayman Chemical, Ann Arbor, Mich).21
Statistics. Numerical data are presented as themean

SEM. Differences between groups were analyzed using an
unpaired t test or one-way analysis of variance (ANOVA),
using Duncan’s multiple-range test post-hoc. Significant
differences (P 	 .05) are indicated.
RESULTS
Remodeling of fistula veins. After creation of an AVF
(Fig 1,A), blood flow in the fistula veins abruptly increased,
reaching more than ninefold higher than controls veins on
day 7 and remained significantly high for 28 days (top panel
in Fig 1, B). WSS peaked on day 3 but decreased thereafter,
although it was still significantly higher than controls
through day 28 (the second panel in Fig 1, B). The in-
creases in blood flow could not be ascribed to altered
intravascular pressure, as this parameter remained un-
changed at all time-points in both groups (the third panel
in Fig 1, B). The internal radius and external width of the
iliac vein increased markedly compared with control veins
by day 7 and the increase continued thereafter (bottom
panel in Fig 1, B). The representative images show venodi-
latation of the fistula side, compared with the contralateral
side, on day 14 and day 28 in AVF rats (Fig 1, C). Despite
venodilatation, the thickness of both the intima and media
in the fistula veins gradually increased to a level significantly
greater than the control group by day 7, and the increases
continued thereafter (top and middle panels in Fig 1, D).However, the intima-to-media (IM) ratio was unchanged
(bottom panel in Fig 1, D).
TRPV expression and hemodynamic changes. We
next examined expression of two TRPV channels during
venous remodeling. In the fistula veins, TRPV1 expression
increased significantly by day 3 and remained at signifi-
cantly higher levels thereafter, compared with control
veins, with a maximum increase of 5.1-fold on day 7 (Fig 2,
A). In contrast, TRPV4 expression was unchanged at all
time points. The increases in TRPV1 mRNA expression
were similar to the increases in protein level, with peak
levels detected on day 7. Again, TRPV4 mRNA expression
was unchanged (Fig 2, B). Immunofluorescence labeling
revealed that TRPV1 was mostly distributed in the endo-
thelial layer of the control veins and this expression was
markedly upregulated in the thickened wall of the 7-day
and 14-day fistula veins (Fig 2, C). No signal was detected
in the negative control. Linear regression analysis revealed a
positive correlation between WSS and TRPV1 protein ex-
pression (R  0.7160, Fig 2, D), but there was no corre-
lation to TRPV4 expression (data not shown). Prevention
of fistula venodilatation significantly reduces blood flow,
WSS, and TRPV1 expression after 28 days (Fig 2, E and F).
However, blood flow restriction showed no effect upon
control veins.
CaMK II signaling and NO dysregulation in fistula
remodeling. As a ubiquitous Ca2-dependent enzyme in
the vasculature,22 we examined whether CaMK II activity is
correlated with enhanced TRPV1 expression. CaMK II
activity calculated by the ratio of phosphorylated to total
protein expression was significantly increased at both 14
and 28 days after creation of AVF in the fistula veins
compared with control veins (Fig 3, A). This change was
associated with a 2.2-fold and 3.1-fold increase in eNOS
expression in 14- and 28-day fistula veins, respectively.
However, iNOS expression was unchanged (Fig 3, B).
eNOS was present in the endothelium and SMCs of the
control veins, but its expression was significantly increased
in the 14- and 28-day fistula veins, and a major change in
protein level was detected in the SMC layer of the fistula
veins (Fig 3,C). Interestingly, increased TRPV1 expression
in the 28-day fistula vein was colocalized primarily with
increased eNOS expression in the endothelial layer.
In addition to the NOS expression, two isoforms of
arginase were also present in veins (Fig 3, D) and possibly
serve as an endogenous competitor for L-arginine.23 The
expression of arginase I, but not arginase II, was signifi-
cantly diminished in the 14- and 28-day fistula veins (upper
panel). Compared with control veins, arginase activity de-
creased at both time points in the fistula veins (lower
panel). These observations indicate that the changes in
arginase activity were due primarily to the downregulation
of arginase I.
We further asked whether the increase in CaMK II
activity affected the expression of eNOS and arginase I.
Treatment of 28-day fistula veins with the specific CaMK II
inhibitor KN-93 significantly attenuated eNOS upregula-
tion and restored arginase I expression, compared with
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CaMK II regulates eNOS and arginase I expression recip-
rocally. Inhibition of CaMK II by KN-93 only slightly
reduced TRPV1 upregulation in the fistula veins (P  .05,
data not shown). The internal diameter and blood flow of
fistula veins were also slightly increased by KN-93 treat-
ment. This causes a significant reduction in WSS compared
with the untreated fistula veins (data not shown).
An imbalance in arginase I and eNOS activity could
cause NO overproduction, and the nitrate and nitrite
(NOx) content, representing NO formation, was deter-
mined to verify the role of NO in the high WSS vessels.
Compared with the control veins, the accumulation of
NOx increased significantly in the 14- and 28-day fistula
veins, with the highest levels at 28 days (Fig 3, F).
The NO increase was, in fact, a predictor of MMP2
activation in the fistula veins because NO targets zinc ions
as well as cysteine residues, which disrupts the cysteine-zinc
interaction in MMP and activates the enzyme.24 Gel zy-
mography demonstrated that the activity of both the
proenzyme and the active form of MMP2 significantly
increased in 14- and 28-day fistula veins compared with
Fig 2. Transient receptor potential vanilloid channel (
TRPV1 and TRPV4 protein levels in the vein (n 2). T
to actin ratio. B, RT-PCR analysis of changes in TRPV1
times.C, TRPV1 (red) is present in endothelium of the c
DAPI (blue). Scale bar: 100 m. D, Linear regression an
veins. E and F, Vessel restriction by ligature reduces bloo
6 in all bar graphs. *P	 .05 compared with control (at th
fistula vein.control veins (Fig 3, G).Capsazepine attenuates fistula remodeling. In con-
trol veins, neither the external width nor the hemodynamic
parameters were affected by treatment with capsazepine or
vehicle (Fig 4, A). Capsazepine also showed little effect on
intravascular pressure in control or fistula veins (data not
shown). However, capsazepine significantly increased the
internal radius and slightly increased the blood flow in
28-day fistula veins compared with untreated veins (upper
and middle panels). Interestingly, high WSS in the 28-day
fistula veins was significantly reduced by capsazepine com-
pared with untreated veins (lower panel).
Capsazepine had no effect on the thickness of the
intima and media of the control veins over the 28-day
experimental period (upper pictures and lower bar graph of
Fig 4, B). However, the drug significantly attenuated vas-
cular remodeling in 28-day fistula veins, as shown by the
simultaneous reductions in thickening of the intima and
media (lower pictures and bar graph). The ratio of intima-
to-media thickness was similar among groups (bottom bar
graph).
Capsazepine reverses downstream signaling for
remodeling. The above observations clearly show that
) expression in veins. A, Representative blots showing
r graphs show a densitometric quantitation of the TRPV
RPV4 mRNA in control (C) and fistula veins at various
l and 7- and 14-day fistula veins. Nuclei are stained with
of wall shear stress (WSS) and TRPV1 protein levels in
and WSS (E) as well as TRPV1 protein levels (F). N
time-point in A). †P	 .05 compared with the untreatedTRPV
he ba
and T
ontro
alysis
d flow
e sameTRPV1 function is important for venous remodeling. We
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Volume 52, Number 5 Chen et al 1315Fig 3. Changes in enzymes controlling nitric oxide (NO) production and metalloproteinases (MMP)2 activation in
veins.A, Western blot shows the expression of phosphorylated and total CaMK II. The bar graph shows the ratio of the
two proteins and represents CaMK II activity. B, Expression of eNOS and iNOS in veins. AU, Arbitrary units of band
density. C, Upper panels show that eNOS (green) is present in the veins, and lower panels show the colocalization
(yellow in merge picture) of transient receptor potential vanilloid channel 1 (TRPV1) (red) and eNOS (green) in
endothelium of a 28-day fistula vein. Nuclei are stained with DAPI (blue). Scale bar: 100 m.D, Expression of arginase
I and II in veins.E, A specific blocker of CaMK II, KN-93, reverses eNOS and arginase I expression in the 28-day fistula
vein. F, Content of two NO metabolites, nitrate and nitrite (NOx), in veins. G, Zymography reveals that both the
proenzyme and active forms of MMP2 have increased activity in the fistula veins. N  6 in all bar graphs. *P 	 .05
compared with the control. †P 	 .05 compared with the untreated fistula vein.
vein.
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role of TRPV1. Treatment of 28-day fistula veins with
capsazepine did not affect the increase in TRPV1 expres-
sion (Fig 5, A), whereas the capsazepine treatment signifi-
cantly reduced CaMK II activation, compared with
untreated veins (Fig 5, B). This result suggests that capsaz-
epine possibly blocks Ca2 entry through TRPV1, but does
not affect its expression. Although CaMK II is a Ca2-
dependent enzyme, we cannot rule out the possibility that
a different pathway, other than the change in [Ca2]i,
caused by capsazepine may lower CaMK II activity directly.
Moreover, the upregulation of eNOS and downregulation
of arginase I in the 28-day fistula veins were reversed by
capsazepine treatment (Fig 5, C). This change was also
correlated with reduced NO formation and MMP2 activity
(Fig 5, D and E). NOx formation, MMP2 activity, and
protein expression in the control veins were not affected by
capsazepine treatment.
DISCUSSION
We have shown here for the first time that the presence
of TRPV1 in the endothelium of the fistula vein is respon-
sive to increased blood flow/WSS in venous remodeling
(Fig 6). Endothelial TRPV1 increases CaMK II activity,
possibly via Ca2 influx, which triggers NO-mediated
MMP2 activation by enhancing eNOS and suppressing
arginase I expression. Chronic inhibition of TRPV1 low-
ered CaMK II activity, rebalanced eNOS and arginase I
Fig 4. Capsazepine attenuates remodeling. A, Hemo
quantitation of changes in the thickness of intima and me
Nuclei are stained by hematoxylin (blue). Scale bar: 20m
veins (C). †P 	 .05 compared with the untreated fistulalevels, and possibly prevented remodeling.Various factors can influence vessel remodeling.25
Wound healing processes, inflammation, and infections
also have a profound effect on the vessels in the wound.26
Our model provides direct evidence that a simple hemody-
namic force, ie, high blood flow or WSS, contributes to
remodeling of the fistula vein in the absence of any effect
caused by surgical wounding. Importantly, several features
present in the rat model of femoral AVF are similar to
clinically constructed AVF used for hemodialysis. First, the
hemodynamic changes, ie, high blood flow and low pres-
sure, resemble those seen in a clinically generated AVF.
Second, there was both outward (venodilatation) and in-
ward (shrinkage) remodeling of the vein that correlated
well with clinical AVF. Third, the vascular remodeling
associated with upregulation of MMPs may account for the
changes in the extracellular matrix (ECM) seen in the
venous segment of the AVF. However, the present AVF
model still has features distinct from the clinically generated
AVF. First, the method of AVF creation is not the same as
the most frequently used clinical approach of anastomosis,
ie, the venous end to arterial side opening technique.
Second, the rat iliac veins belong to the deep venous system
in contrast to the superficial veins used in uremic patients.
Correction of high blood flow by narrowing the exter-
nal diameter of the fistula veins not only significantly
blocked the flow/WSS increase, but also prevented fistula
remodeling over the 28-day experimental period (Fig 2, E
and F). These results clearly indicate that high flow/WSS is
mic changes in veins. B, Representative images and
nd the ratio of intima to media (IM) in the venous wall.
6 in all bar graphs. *P	 .05 compared with the controldyna
dia, a
. Nthe primary factor required to cause venous remodeling of
	 .0
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veins to detect hemodynamic changes. As a mechanosensi-
tive channel, TRPV channels expressed in various tissues
are activated by a broad range of mechanical stimuli.27,28
Our results are consistent with previous observations, but
only TRPV1 responds to high blood flow in the fistula vein,
Fig 5. Effects of transient receptor potential vanilloid
showing TRPV1 expression, CaMK II activity, or eNOS
of capsazepine treatment. D, Nitric oxide (NO) metabo
the activity of both the proenzyme and the active form
graphs. *P 	 .05 compared to the control veins (C). †P
Fig 6. Model showing how transient receptor potential vanilloid
channel 1 (TRPV1) contributes to high blood flow-induced ve-
nous remodeling.as TRPV4 expression was not affected by high flow orfistula remodeling (Fig 2, A and Fig 5, F). Substantial
evidence has emerged indicating that several TRP isoforms
may contribute to SMC differentiation during vascular
injury.7 In organ cultures of human saphenous veins, the
expression of type 1 canonical TRP (TRPC1) was increased
in the neointimal growth region of SMCs and application
of a TRPC1-specific antibody effectively prevented intralu-
minal narrowing.29 Oancea et al30 provided intriguing
evidence that in HEK293T cells, exposure to fluid flow
rapidly increases the level of the endogenous type 7
melastatin TRP (TRPM7) protein in the plasma mem-
brane. A previous study has demonstrated that the func-
tional TRPV1 channel is a tetramer and that the four
subunits interact via the TRP-like domain before trafficking
to the plasma membrane.31 However, this nontranscrip-
tional regulation of TRPV1 is probably not seen in our
fistula veins because we show that both the protein and
mRNA levels of TRPV1 are increased (Fig 2, A and B).
Mechanosensitive channels (MSCs) can be directly acti-
vated by force conveyed through lipid tension or structure-
nel 1 (TRPV1) blockade. A through C, Western blots
arginase I expression in veins in the presence or absence
NOx) in the veins. E, Zymography revealing changes in
talloproteinases (MMP)2 in the veins. N  6 in all bar
5 compared with the untreated fistula vein.chan
and
lites (
of melinking proteins that respond to the force parallel to the cell
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stretch applied to human pulmonary microvascular endo-
thelial cells pulled actin-based cytoskeletal stress fibers that
in turn, opened TRPV channels. Force also can be detected
by a mechanosensitive protein without a channel pore
structure which, in turn, triggers production of second
messengers that carry the signal to specific TRPV channels
for indirect activation.11,12,32 Elevation of intravascular
pressure in rat mesenteric arteries was shown to generate
the arachidonate metabolite in SMCs, which subsequently
activated TRPV1 for regulation of vascular tone.11 TRPV4
is present in the endothelium of the rat carotid artery
and causes vasodilatation in response to shear stress; this
effect is dependent on the action of PLA2.
12 These results
indicate that an upstream factor is present and acts as the
real mechanosensor to induce lipid metabolite generation
for TRPV activation. However, whether arachidonate-
mediated signal transduction or actin cytoskeleton partici-
pated in TRPV1-induced venous remodeling requires de-
tailed studies.
CaMK II in the endothelium is activated by oscilla-
tory or large WSS in vessels with atherosclerotic le-
sions.34 Our results also show that the increased CaMK
II activity in the fistula veins. This, however, is depen-
dent on TRPV1 because capsazepine markedly attenu-
ated CaMK II activity (Fig 5, B). Because the potential
target of increased CaMK II activity is eNOS,22 the
TRPV1-mediated increase in CaMK II activity in our
fistula veins may directly stimulate eNOS activity/ex-
pression and enhance NO formation during remodeling.
Not only an elevation of eNOS expression, but also a
reduction in the expression of the endogenous NOS
competitor arginase I, is responsible for the increase in
NO in the fistula veins (Fig 3, D). Two arginases are
present in the endothelium and SMCs of the aorta and
coronary artery of various mammalian species.35 Here,
we showed that both arginase I and II were present in the
rat iliac vein. However, arginase I is the dominant iso-
form and contributes to changes in the total arginase
activity in the 28-day fistula veins (Fig 3, D). Low
arginase expression/activity makes more L-arginine
available for eNOS and can also lead to generation of
superoxide anions if eNOS becomes “uncoupled”. A
recent study has reported that an increase in arginase I
expression/activity plays an integral role in the remod-
eling response of rat carotid arteries after injury by
balloon inflation.35 However, we found a sustained
downregulation and low activity of arginase I in venous
remodeling that was controlled by CaMK II activity (Fig
3). Different vascular tissues and the degree of injury
may be the cause of this discrepancy.
A gradual increase in NO formation was seen during
fistula remodeling (Fig 3, F). NO or peroxynitrite
(ONOO-), which result from simultaneous production
of NO and superoxide, activates MMPs.24 Pro-MMP2
can be activated by removal of the auto-inhibitory
propeptide resulting in an active truncated MMP2. In
the rabbit AVF, high blood flow in the left commoncarotid artery after creating a fistula to the external
jugular vein induced NO production, which in turn
increased the amount of the 62-kDa active form of
MMP2.36 Our gelatin zymography assay showed similar
results in that the activity of both the pro-enzyme and
the active MMP2 gradually increased in fistula veins (Fig
3, G). NO and ONOO- can directly react with the
cysteine residue in the propeptide domain of MMP2 and
disrupt its binding to the catalytic Zn2 ion, thereby
activating the full-length pro-MMP2.24 Therefore, in-
creases in both the full-length and active form of MMP2
possibly contribute to ECM remodeling of fistula veins.
In regard to other effects possibly mediated by TRPV1,
the previous study has shown that Ca2 entry via TRP
channels regulate SMC tone by activation of voltage-
dependent Ca2 channels or enhancedCa2 spark activity of
ryanodine receptors and the activity of large-conductance
Ca2-sensitive K channels.37 Moreover, TRPV1 can be
phosphorylated by several kinases including CaMK II, the
dynamic balance between the rate of phosphorylation and
dephosphorylation controls TRPV1 activity.31 Together
with unchanged TRPV1 upregulation in the KN-93-
treated fistula veins, we speculate that increased CaMK II
activity in the fistula veins only affect channel activity but
not protein level of TRPV1. Membrane stretch activates
several Gq-coupled receptors,38 which then increase phos-
pholipase C (PLC) activity, in a large array of cells and
tissues.39 PLC elevates cellular levels of PIP2, DAG, and
IP3, all of which have been demonstrated to influence TRP
channel activity. Interestingly, protein kinase C-dependent
phosphorylation of TRPV1 occurs downstream of activa-
tion of Gq-coupled receptors.31 However, which of the
above mechanisms is involved in enhanced TRPV1 func-
tion in the fistula veins requires further study.
Though the venous segment of the AVF produces a
vasodilator response to reduce WSS, the persistent pres-
ence of high blood flow causes wall thickening in the
fistula veins and creates more tensile stress than found in
control veins as a result of the high WSS (Fig 1, B), which
eventually results in exaggerated remodeling. We re-
stricted the high blood flow in fistula veins and showed
that this treatment attenuates WSS and TRPV1 upregu-
lation (Fig 2, E and F). This indicates that physical
factors is primarily responsible for wall thickening. How-
ever, flow restriction is not practical in clinical settings
because high flow is required for blood delivery during
dialysis. Interestingly, TRPV1 inhibition markedly re-
duced WSS-induced remodeling and did not affect other
hemodynamic changes such as high blood flow (Fig 4).
Moreover, capsazepine treatment showed little effect on
the increased level of pro-MMP2 in the fistula veins (Fig
5, E). This indicates that the fistula veins still accumulate
pro-remodeling molecules, but components such as
TRPV1, which initiate remodeling, are blocked. We
therefore speculate that blockade of TRPV1 function
may delay or optimize venous remodeling during matu-
ration.
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 5 Chen et al 1319CONCLUSION
Our results indicate that TRPV1 is essential in the
remodeling of fistula veins, and that WSS leads to
TRPV1 upregulation. Blockade of the sensor function of
TRPV1 prevents venous thickening and makes fistula
veins more distensible when challenged with a similar
high flow.
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